Koers Atossa Genetics Inc Nasdaq
Aandelen
US04962H2094
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 202 mln. 187 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -32 mln. -29,49 mln. | Nettowinst (verlies) 2025 * | -39 mln. -35,94 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-6,44
x | K/w-verhouding 2025 * |
-5,55
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,55% |
Recentste transcriptie over Atossa Genetics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Shu-Chih Chen
FOU | Founder | 62 | 01-12-08 |
Steven Quay
CEO | Chief Executive Officer | 73 | 01-12-08 |
Heather Rees
DFI | Director of Finance/CFO | - | 01-01-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Steven Quay
CEO | Chief Executive Officer | 73 | 01-12-08 |
Director/Board Member | 66 | 01-03-14 | |
H. Remmel
BRD | Director/Board Member | 72 | 01-02-12 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+33,37% | 50,85 mld. | |
+1,55% | 42,82 mld. | |
+49,28% | 42,03 mld. | |
-4,22% | 29,55 mld. | |
+11,57% | 26,11 mld. | |
-21,00% | 19,13 mld. | |
+7,36% | 13,05 mld. | |
+28,30% | 12,16 mld. | |
+23,80% | 12,08 mld. |